Extended Data Fig. 7: Elovl1-deficient CD8+ T cells increased mitochondrial functionality.
a, Quantification of mitochondrial fragmentation via confocal microscopy of sgNT and sgElovl1 OT-I T cells at day 7 from in vitro activation (sgNT=30; sgElovl1=30; three independent experiments). b, Quantification of Basal (OCRBAS), Maximal (OCRMAX), and Spare respiratory capacity (SRC), based on seahorse data of sgNT and sgElovl1 OT-I T cells 7 days after in vitro activation (n=3, five technical replicates). c, d, Representative oxygen consumption rate (OCR) profile of human CD8+ T cells treated with ELOVL1 inhibitor (C3) or vehicle (DMSO) at day 7 from in vitro activation (c) and quantification of Basal (OCRBAS), Maximal (OCRMAX), and Spare respiratory capacity (SRC), based on seahorse data (d) (n=3). e, ATP citrate lyase (Acly) expression assessed by qRT-PCR in vitro in sgNT or sgElovl1 OT-I T cells (n=4). f-h, Abundance of total 13C-labelled cellular Succinate (f), Malate (g), and Pyruvate (h) derived from 13C-Glucose (n=5). i, j, Abundance of total 13C-labelled cellular Citrate (i) and α-Ketoglutarate (j) derived from 13C-Palmitate (n=5). k, Schematics of in vitro differentiation memory assay. l, Quantification of central memory T cells (CD62L+ CD44+) in CD8+ T cells treated with C3 or control DMSO, upon in vitro differentiation with IL-7 and IL-15 (n=3). Data are presented as the mean ± s.e.m. Statistical significance was assessed by unpaired (a, b, f-j) or paired (d, e, l) two-tailed Student’s t-test.
